Milea Timbergen

73 20 . van Broekhoven DL, Verhoef C, Grunhagen DJ, van Gorp JM, den Bakker MA, Hinrichs JW, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol. 2015;22(5):1464-1470. 21 . Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18(47):6615-6620. 22 . Domont J, Salas S, Lacroix L, Brouste V, Saulnier P, Terrier P, et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer. 2010;102(6):1032-1036. 23 . Enzo MV, Rastrelli M, Rossi CR, Hladnik U, Segat D. The Wnt/beta-catenin pathway in human fibrotic- like diseases and its eligibility as a therapeutic target. Mol Cell Ther. 2015;3:1. 24 . Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science. 2000;287(5458):1606-1609. 25 . Willert K, Nusse R. Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev. 1998;8(1):95-102. 26 . Nusse R, Clevers H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169(6):985-999. 27 . Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461-1473. 28 . Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434(7035):843-850. 29 . Rebouissou S, Franconi A, Calderaro J, Letouze E, Imbeaud S, Pilati C, et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression. Hepatology. 2016;64(6):2047-2061. 30 . Garvey PB, Booth JH, Baumann DP, Calhoun KA, Liu J, Pollock RE, et al. Complex reconstruction of desmoid tumor resections does not increase desmoid tumor recurrence. Journal of the American College of Surgeons. 2013;217(3):472-480. 31 . Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer. 2013;119(20):3696-3702. 32 . Hamada S, Futamura N, Ikuta K, Urakawa H, Kozawa E, Ishiguro N, et al. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: A pilot study. PLoS ONE. 2014;9(5). 33 . Hamada S, Urakawa H, Kozawa E, Arai E, Ikuta K, Sakai T, et al. Characteristics of cultured desmoid cells with different CTNNB1 mutation status. Cancer Med. 2016;5(2):352-360. 34 . Salas S, Brulard C, Terrier P, Ranchere-Vince D, Neuville A, Guillou L, et al. Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival. Clin Cancer Res. 2015;21(18):4194-4200. 35 . Nusse R, Lim X. the Wnt homepage, Wnt Target genes, https://web.stanford.edu/group/nusselab/cgi-bin/ wnt/target_genes. Access date 06-03-2018 36 . Denys H, Jadidizadeh A, Amini Nik S, Van Dam K, Aerts S, Alman BA, et al. Identification of IGFBP-6 as a significantly downregulated gene by beta-catenin in desmoid tumors. Oncogene. 2004;23(3):654-664. 37 . Cheon SS, Cheah AY, Turley S, Nadesan P, Poon R, Clevers H, et al. beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S A. 2002;99(10):6973-6978. 38 . Nishita M, Enomoto M, Yamagata K, Minami Y. Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol. 2010;20(6):346-354. 39 . Duchartre Y, Kim YM, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016;99:141-149. 40 . Saito T, Oda Y, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y, et al. beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours. J Pathol. 2001;195(2):222-228. 41 . Colombo C, Urbini M, Astolfi A, Collini P, Indio V, Belfiore A, et al. Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis. Genes Chromosomes Cancer. 2018;57(10):495-503. 3